[go: up one dir, main page]

WO1996039126A3 - Sels de ranitidine comprenant du trisilicate de magnesium utilises comme adsorbats - Google Patents

Sels de ranitidine comprenant du trisilicate de magnesium utilises comme adsorbats Download PDF

Info

Publication number
WO1996039126A3
WO1996039126A3 PCT/US1996/008978 US9608978W WO9639126A3 WO 1996039126 A3 WO1996039126 A3 WO 1996039126A3 US 9608978 W US9608978 W US 9608978W WO 9639126 A3 WO9639126 A3 WO 9639126A3
Authority
WO
WIPO (PCT)
Prior art keywords
adsorbate
ranitidine
magnesium trisilicate
salts
ranitidine salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/008978
Other languages
English (en)
Other versions
WO1996039126A2 (fr
Inventor
Albert F Sorg
Kirti H Valia
Anthony B Eoga
John Denick Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Priority to AU63787/96A priority Critical patent/AU6378796A/en
Publication of WO1996039126A2 publication Critical patent/WO1996039126A2/fr
Publication of WO1996039126A3 publication Critical patent/WO1996039126A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte à un adsorbat de ranitidine, sur du trisilicate de magnésium, destiné à être administré par voie orale et qui n'a pas le goût amer et déplaisant associé à la ranitidine. La ranitidine incluse dans l'adsorbat se présente sous une forme stable et amorphe et est compatible avec des excipients pharmaceutiquement acceptables.
PCT/US1996/008978 1995-06-06 1996-06-05 Sels de ranitidine comprenant du trisilicate de magnesium utilises comme adsorbats Ceased WO1996039126A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63787/96A AU6378796A (en) 1995-06-06 1996-06-05 Ranitidine salts on magnesium trisilicate as an adsorbate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46821695A 1995-06-06 1995-06-06
US08/468,216 1995-06-06

Publications (2)

Publication Number Publication Date
WO1996039126A2 WO1996039126A2 (fr) 1996-12-12
WO1996039126A3 true WO1996039126A3 (fr) 1997-01-30

Family

ID=23858888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/008978 Ceased WO1996039126A2 (fr) 1995-06-06 1996-06-05 Sels de ranitidine comprenant du trisilicate de magnesium utilises comme adsorbats

Country Status (2)

Country Link
AU (1) AU6378796A (fr)
WO (1) WO1996039126A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
SK15742003A3 (sk) 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutická kompozícia zahrnujúca adsorbát amorfného liečiva
WO2005023225A1 (fr) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Adsorbat de cilostazol
EP2072042A1 (fr) * 2007-12-21 2009-06-24 Lek Pharmaceuticals D.D. Ingrédient pharmaceutique actif sur support solide amorphe et avec solubilité améliorée
EP2238979A1 (fr) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Ingrédient pharmaceutique actif absorbé sur un support solide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636532A1 (fr) * 1988-09-20 1990-03-23 Glaxo Group Ltd Compositions pharmaceutiques
EP0526862A1 (fr) * 1991-08-06 1993-02-10 VECTORPHARMA INTERNATIONAL S.p.A. Compositions pharmaceutiques solides pour l'administration orale à séjour gastrique prolongé

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636532A1 (fr) * 1988-09-20 1990-03-23 Glaxo Group Ltd Compositions pharmaceutiques
EP0526862A1 (fr) * 1991-08-06 1993-02-10 VECTORPHARMA INTERNATIONAL S.p.A. Compositions pharmaceutiques solides pour l'administration orale à séjour gastrique prolongé

Also Published As

Publication number Publication date
AU6378796A (en) 1996-12-24
WO1996039126A2 (fr) 1996-12-12

Similar Documents

Publication Publication Date Title
USD423786S (en) Combined tooth and tongue brush with timing device
USD446959S1 (en) Side chair
USD391783S (en) Entertainment side unit
AU5391490A (en) Pharmaceutical formulation
CA2123160A1 (fr) Formulation a liberation controlee
USD314473S (en) Adjustable settee
MX9803344A (es) Formulacion farmaceutica liofilizada, estable.
USD341424S (en) Post operative bunion splint
AU7305594A (en) Physiologically active substance-prolonged releasing-type pharmaceutical preparation
EP0839526A3 (fr) Préparation pharmaceutique solide à dissolution ou désintégration buccale rapide
CA2259148A1 (fr) Formes posologiques solides de valsartan administrees par voie orale
AU5515296A (en) Composition for oral administration
AU2003238221A1 (en) Ibuprofen suspension
AU8631891A (en) Isoxazole compound, pharmaceutically acceptable salt thereof, and medicinal use thereof
WO2000071108A3 (fr) Procedes de traitement de l'asthme a l'aide de s-oxybutynine
USD451971S1 (en) Exercise device
USD341263S (en) Club chair
EP1440691A3 (fr) Traitement des troubles neurotiques
USD430748S (en) Chair
WO1996039126A3 (fr) Sels de ranitidine comprenant du trisilicate de magnesium utilises comme adsorbats
USD387165S (en) Retaining device for maintaining corrected dentition
USD377452S (en) Child's timing device for monitoring potty time
USD414401S (en) Cam tie down buckle
USD435190S (en) Insulated jug
USD450940S1 (en) Ottoman

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX NZ SG

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP MX NZ SG

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA